Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Frederick

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
The Journal of Prevention of Alzheimer'S Disease|January 31, 2022
Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic ReviewA R Shaw, J Perales-Puchalt, E Johnson, et al.
Atherosclerosis|October 20, 2009
CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(-/-) miceRobert J Aiello, Bret D Perry, Patricia-Ann Bourassa, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 28, 2014
Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interactionS J Brantley, B T Gufford, R Dua, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2025
Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: Contrasting effects of once versus twice daily dosingSteven M Weldon, Derek A Cogan, Matthew A Cerny, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 2, 2014
Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubilityAmit S Kalgutkar, Kosea S Frederick, Heather L Hatch, et al.
British Journal of Haematology|September 17, 2013
Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosisPatricia T Greipp, Stephanie A Smoley, David S Viswanatha, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 2, 2013
Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alphaAmit S Kalgutkar, Danny Chen, Manthena V Varma, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 10, 2007
Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and humanAmit S Kalgutkar, Bo Feng, Hang T Nguyen, et al.
Neurology|November 14, 2001
Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trialC S Kase, A J Furlan, L R Wechsler, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2017
Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activityKenneth Meyers, Derek A Cogan, Jennifer Burke, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
The Journal of Prevention of Alzheimer'S Disease|January 31, 2022
Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic ReviewA R Shaw, J Perales-Puchalt, E Johnson, et al.
Atherosclerosis|October 20, 2009
CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(-/-) miceRobert J Aiello, Bret D Perry, Patricia-Ann Bourassa, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 28, 2014
Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interactionS J Brantley, B T Gufford, R Dua, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2025
Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: Contrasting effects of once versus twice daily dosingSteven M Weldon, Derek A Cogan, Matthew A Cerny, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 2, 2014
Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubilityAmit S Kalgutkar, Kosea S Frederick, Heather L Hatch, et al.
British Journal of Haematology|September 17, 2013
Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosisPatricia T Greipp, Stephanie A Smoley, David S Viswanatha, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 2, 2013
Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alphaAmit S Kalgutkar, Danny Chen, Manthena V Varma, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 10, 2007
Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and humanAmit S Kalgutkar, Bo Feng, Hang T Nguyen, et al.
Neurology|November 14, 2001
Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trialC S Kase, A J Furlan, L R Wechsler, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2017
Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activityKenneth Meyers, Derek A Cogan, Jennifer Burke, et al.
Pageof 5